Release date: December 15, 2017
Expiration date: December 15, 2018
Estimated time to complete the activity: 1.75 hours
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower (www.annenberg.net) and Medtelligence in collaboration with Postgraduate Institute for Medicine.
This activity is supported by an independent medical educational grant from Janssen Scientific Affairs, LLC.
This online activity features slides and a transcription of the speakers’ presentations from a live meeting held on October 30, 2017. Internationally renowned experts discuss the clinical issues and recent data regarding antiplatelet/anticoagulation in patients with coronary artery disease (CAD). This activity evaluates the data, clinical implications, and recommendations in secondary prevention of CAD, where an anticoagulation management strategy has increasingly shown benefits to patients by providing clot formation and embolization protection with NOACs with acceptable bleeding risks.
This activity has been designed to meet the educational needs of Interventional Cardiologists, Cardiologists, Fellows, and other Healthcare Professionals involved in the care of patients with coronary artery disease.
After completing this activity, the participant should be better able to:
- Describe the rationale for combining an anticoagulant with antiplatelet therapy after stenting
- Relate the clinical implications of anticoagulation in CAD, based on recent data
- Utilize NOACs at the proper dose for patients with moderate or high risk of stroke, advising patients of the risks and benefits, and performing proper follow-up
- Apply guideline recommendations for secondary prevention of CAD after ACS or PCI and discuss the proposed changes that have been recommended based on recent data
Christopher B. Granger, MD, Chair
Professor of Medicine
Division of Cardiology
Director, Cardiac Intensive Care Unit
Duke University Medical Center
Neal S. Kleiman, MD
Program Director of Interventional Cardiology
Professor of Medicine
Weill Cornell Medical College
Director, Cardiac Catheterization Laboratories
Houston Methodist DeBakey Cardiology Associates
Freek W. A. Verheugt, MD, PhD
Department of Cardiology
Onze Lieve Vrouwe Gasthuis (OLVG)
PHYSICIAN CONTINUING MEDICAL EDUCATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Medtelligence. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE AND CONFLICT OF INTEREST
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The Annenberg Center for Health Sciences at Eisenhower is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Dr. Granger: Contracted Research: Armetheon, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Duke Clinical Research Institute, GlaxoSmithKline, Medtronic Foundation, and Pfizer; Research Support: Armetheon, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Duke Clinical Research Institute, FDA, GlaxoSmithKline, Janssen, Medtronic Foundation, Novartis, and Pfizer; Consulting Fees: Abbvie, Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Gilead, GlaxoSmithKline, Janssen, Medscape, Medtronic, Merck, NIH, Novartis, Pfizer, Sirtex, and Verseon.
- Dr. Kleiman: Nothing to disclose.
- Dr. Verheugt: Consulting Fees: Bayer, Daiichi-Sankyo, BMS, and BI.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.
Charles E. Willis, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower consults for Pfizer, Inc.; Amanda Sewell, MBA, Manager of Continuing Education and Alma Perez, Accreditation Specialist, both of the Annenberg Center for Health Sciences at Eisenhower, have no relevant commercial relationships to disclose.
Medtelligence: Ben Caref, PhD; Pamela Clark – No financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period December 15, 2017 through December 15, 2018, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID #13076. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.
If you have any questions regarding the CME certification of this activity, please contact Postgraduate Institute for Medicine at: firstname.lastname@example.org or (303) 799-1930.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Course Viewing Requirements
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above